Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-10-12
2011-12-20
Sitton, Jehanne (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C536S024300
Reexamination Certificate
active
08080374
ABSTRACT:
Described herein are methods for diagnosing increased risk of cardiovascular disease in a subject, based on the presence or absence of polymorphisms in the D36 gene.
REFERENCES:
patent: 6322976 (2001-11-01), Aitman et al.
rs1984112; dbSNP; National Library of Medicine, Jan. 2001.
Hanawa et al; J. Med. Genet. vol. 39, pp. 286-291, 2002.
rs1761667 (dbSNP; Nov. 2000).
Ma et al; Human Molecular Genetics, vol. 13, 2004, pp. 2197-2205.
(ss3324602, dbSNP build 110, Oct. 2001.
International Search Report and Written Opinion for International Application No. PCT/US05/16370, 14 pages (Feb. 17, 2006).
Hanawa et al., “Identification of cryptic splice site, exon skipping, and novel point mutations in type I CD36 deficiency,” J. Med. Genet., 39:286-291 (2002).
Ma et al., “A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians,” Human Molecular Genetics, 13(19):2197-2205 (2004).
Tanaka et al., “Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations,” J. Lipid Res., 42:751-759 (2001).
Abumrad et al., “Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36,” J. Biol. Chem., 268:17665-17668, (1993).
Aitman et al., “Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats,” Nat. Genet., 21:76-83, (1999).
Chen et al., “Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL,” Arterioscler. Thromb. Vasc. Biol., 21:372-7 (2001).
Endemann, et al., “CD36 is a receptor for oxidized low density lipoprotein,” J. Biol. Chem., 268:11811-11816, (1993).
Febbraio, et al., “A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism,” J. Biol. Chem., 274:19055-19062, (1999).
Febbraio et al., “CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism,” J. Clin. Invest., 108:785-791, (2001).
Furuhashi et al., “Insulin sensitivity and lipid metabolism in human CD36 deficiency,” Diabetes Care, 26:471-474, (2003).
Goudriaan et al., “CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice,” J. Lipid. Res., 44:2270-2277, (2003).
Greenwalt et al., “Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine,” Blood, 80:1105-1115, (1992).
Hajri et al., “Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice,” J. Clin. Invest., 109:1381-1389, (2002).
Hirano et al., “Pathophysiology of human genetic CD36 deficiency,” Trends Cardiovasc. Med., 13:136-41, (2003).
Ibrahimi et al., “Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport,” Proc. Natl. Acad. Sci. U. S. A., 93:2646-2651, (1996).
Kajihara et al., “Association of the Pro90Ser CD36 mutation with elevated free fatty acid concentrations but not with insulin resistance syndrome in Japanese,” Clin. Chim. Acta., 314:125-130, (2001).
Kashiwagi et al., “Molecular basis of CD36 deficiency. Evidence that a 478C→T substitution (proline90→serine) in CD36 cDNA accounts for CD36 deficiency,” J. Clin. Invest., 95:1040-1046, (1995).
Kuniyasu et al., “CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes,” FEBS Letters, 537:85-90, (2003).
Laws et al., “Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations,” Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Arteriosclerosis, Thrombosis, and Vascular Biology, 17:64-71, (1997).
Lewis et al., “Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes,” Endocr. Rev., 23:201-229, (2002).
Miyaoka et al., “CD36 deficiency associated with insulin resistance,” Lancet, 357:686-687, (2001).
Pravenec et al., “Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats,” Nat. Genet., 27:156-158, (2001).
Qi, et al, “Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone,” J. Biol. Chem., 277:48501-48507, (2002).
Ruiz-Velasco et al., “Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in station-induced CD36 expression,” Biochem. Pharmacol, 67:303-13 (2004).
Sato et al., “Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands,” J. Biol. Chem., 277, 15703-15711, (2002).
Stahlberg et al., “Female-predominant expression of fatty acid translocase/CD36 in rat and human liver,” Endocrinology, 145:1972-1979 (2004).
Steinberg, “Low density lipoprotein oxidation and its pathobiological significance,” J. Biol. Chem., 272:20963-20966, (1997).
Tandon et al., “Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion,” J. Biol. Chem., 264:7576-7583, (1989).
Tontonoz et al., “PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, 93, 241-252, (1998).
Warram et al., “Epidemiology of non-insulin-dependent diabetes mellitus and its macrovascular complications. A basis for the development of cost-effective programs,” Endocrinol. Metab. Clin. North Am., 26:165-88, (1997).
Doria Alessandro
Ma Xiaowei
Clauss Isabelle M.
Joslin Diabetes Center, Inc.
Maraia Joseph M.
Pierce Atwood LLP
Sitton Jehanne
LandOfFree
Methods of diagnosing cardiovascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of diagnosing cardiovascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing cardiovascular disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4303991